Coherus Oncology (US.CHRS)
资本配置审计 · 期间： 2012 – 2026
核心指标
US.CHRS · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -96.9% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.65 | ↓ |
| Gross Margin | 69.7% | ↑ |
US.CHRS (Coherus Oncology) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -96.9% ↓ Cash Conversion - → D/E Ratio 0.65 ↓ Gross Margin 69.7% ↑
核心指标
US.CHRS (Coherus Oncology) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -96.9% ↓Cash Conversion - →D/E Ratio 0.65 ↓Gross Margin 69.7% ↑免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies